. 2019 Jan 19;11(2):467–479. doi: 10.18632/aging.101752

Table 3. The association between eight-lncRNA signature and DFS of NSCLC patients in discovery and validating groups.

Variable

Discovery Group

Validation Group-1

Validation Group-2

Number
(High/Low)

HR (95%CI)

P
value

Number
(High/Low)

HR (95%CI)

P value

Number
(High/Low)

HR (95%CI)

P
value

Total

228/228

2.61 (1.91-3.67)

<0.001

335/335

1.45 (1.11-1.91)

0.006

65/65

3.05 (1.58-5.26)

<0.001

Gender

Male

196/160

2.64 (1.74-3.63)

<0.001

209/212

1.31 (0.93-1.86)

0.120

34/26

7.45 (2.16-10.36)

<0.001

Female

63/107

2.25 (1.23-5.41)

0.013

126/123

1.70 (1.10-2.63)

0.018

31/39

1.28 (0.50-3.25)

0.603

Smoking history

Never smoker

2/15

3.89 (0.92-157.30)

0.065

22/29

0.65(0.27-1.60)

0.366

24/43

1.26(0.47-3.42)

0.638

Ever smoker

20/53

3.26 (1.57-12.45)

0.005

217/237

1.43(1.01-2.02)

0.040

41/22

8.17(1.80-8.60)

0.001

Current smoker

10/39

1.33 (0.33-5.54)

0.665

84/59

1.62(0.93-2.82)

0.093

0/0

Histology

Squamous Carcinoma

107/69

3.08 (1.40-4.67)

0.002

219/196

1.46 (1.00-2.12)

0.048

0/0

Adenocarcinoma

86/165

2.50 (1.73-5.48)

<0.001

116/139

1.57 (1.05-2.35)

0.021

0/0

AJCC stage

Stage I

165/193

2.40 (1.61-3.81)

< 0.001

180/174

1.61 (1.06-2.44)

0.021

43/54

2.52 (1.15-5.64)

0.022

Stage II

46/54

2.20 (1.14-4.66)

0.021

97/86

1.25 (0.76-2.06)

0.382

22/11

2.67 (0.85-5.92)

0.104

Stage III

35/6

3.68 (1.30-6.70)

0.015

54/57

1.21 (0.65-2.25)

0.552

0/0

Stage IV

5/4

0.31 (0.00-2.29)

0.221

3/13

0.635

0/0

Abbreviations: HR, Hazard ratio; 95%CI, 95% confidence interval; AJCC, the American Joint Committee on Cancer.